Skip to main content
Indian Journal of Ophthalmology logoLink to Indian Journal of Ophthalmology
. 2025 Jul 18;73(11):1576–1580. doi: 10.4103/IJO.IJO_348_25

Clinical outcomes of cyclophosphamide therapy in relentless placoid choroiditis: A descriptive case series

Miguel Pedroza-Seres 1,✉, Carlos E Rodríguez-López 1
PMCID: PMC12659821  PMID: 40679427

Abstract

Purpose:

To describe the clinical presentation and visual outcomes of relentless placoid choroiditis (RPC) in four patients treated with intravenous cyclophosphamide, a treatment not extensively studied in this condition.

Background:

RPC is a rare and recently described ocular disease characterized by a prolonged and progressive clinical course, widespread lesions, and unknown etiology. There is no consensus on its treatment, and the use of cyclophosphamide in RPC has not been extensively studied.

Case Presentation:

Four RPC patients treated with intravenous cyclophosphamide showed significant visual improvement (mean best-corrected visual acuity [BCVA] improved from 20/125 to 20/32) with minimal side effects.

Conclusion:

This case series demonstrates favorable outcomes with intravenous cyclophosphamide in RPC, supporting its potential as a safe, effective, and cost-efficient treatment option.

Keywords: Choroid diseases, choroiditis, cyclophosphamide, posterior uveitis, relentless placoid chorioretinitis, white dot syndromes


Relentless placoid choroiditis (RPC), also known as ampiginous choroiditis, is a rare ocular disease recently described, characterized by a prolonged and progressive clinical course. RPC belongs to the same spectrum of diseases as acute posterior multifocal placoid pigment epitheliopathy (APMPPE) and serpiginous choroiditis but is distinguished by its more aggressive and treatment-resistant course.[1,2,3]

The disease typically occurs bilaterally and affects equally males and females, typically presenting between the ages of 20 and 60.[4] The cause of RPC is unknown, but it has been associated with autoimmune diseases.[2] A possible neurotropic infectious etiology has been proposed for acute RPC based on findings from animal models of viral neurotropic retinal infections.[5]

Patients with RPC may present with symptoms such as blurred vision, metamorphopsia, pericentral scotomas, photopsia, and/or floaters. RPC is distinguished by the presence of multiple large yellow-white lesions predominantly located in the posterior pole of the eye, which can lead to significant vision loss.[4] A characteristic feature of RPC is the potential occurrence of numerous lesions affecting both the anterior and posterior segments of the equator, differing from APMPPE, which typically confines its lesions to the posterior pole.[1,4]

In autofluorescence (FAF), generalized hypoautofluorescence is typically observed in the posterior pole and mid-peripheral retina. Acute lesions appear hyperfluorescent, while older lesions show hypofluorescence.[3] Optical coherence tomography (OCT) commonly reveals subfoveal fluid, macular pigment epithelium detachment, and hyperreflectivity of the inner and outer layers of the retina.[4,6,7]

Treatment strategies typically involve systemic corticosteroids, with adjunctive use of immunomodulatory therapy as needed. Long-term studies indicate that good visual acuity can be maintained, albeit with a relapse rate of approximately 35%.[2] Despite attempts using a combination of cyclosporine and prednisolone to reduce lesion recurrence, efficacy has often been limited in documented cases.[8] Biologic agents such as adalimumab, infliximab, and mycophenolate mofetil are currently under investigation for their potential to decrease the required dosage of concurrent immunosuppressive agents.[9] This study is a descriptive observational case series based on electronic health records from patients diagnosed with RPC at two tertiary referral centers in Mexico: a high-volume uveitis service in Mexico City and a specialized private ophthalmology clinic in Guadalajara, Jalisco.

The primary outcome was the effectiveness of intravenous cyclophosphamide (10 mg/kg/dose) in treating patients with RPC. Data collected included demographic, clinical, and paraclinical information at both initial and final visits. All patients were screened for infectious diseases using the Venereal Disease Research Laboratory Test (VDRL), Purified Protein Derivative (PPD) test, and Fluorescent Treponemal Antibody Absorption Test (FTA–Abs). Comprehensive blood and urine tests were also conducted. Premedication with antiemetic drugs was administered prior to treatment.

First Case

A 20-year-old female presented with decreased visual acuity and photopsias in the left eye (OS) for one week. She reported a similar episode 12 years ago involving both eyes (OU). At that time, macular edema of unknown etiology was diagnosed and resolved without treatment. Best-corrected visual acuity (BCVA) was 20/40 in the right eye (OD) and counting fingers at one foot in OS. Intraocular pressure (IOP) was 14 mmHg and 15 mmHg, respectively. The anterior chamber showed no signs of inflammation in either eye, or low-grade vitreous cellularity was found in OD. The OS had multiple atrophic retinal lesions with some exudative changes widespread on the posterior pole.

Laboratory results showed an increase in white blood cell count (11400 cells/mL) and normal blood chemistry. VDRL, PPD, FTA–Abs, rheumatoid factor (RF), and antinuclear antibodies (ANA) were all negative. The urine test showed no abnormalities.

In the fluorescein angiography test (FA), the retinal lesions showed an alternating hyperfluorescent and hypofluorescent pattern that increased during the examination. This was due to blockage and scarring processes in the retina and choroid. Macular OCT showed a general increase in retinal thickness in the affected areas [See Fig. 1].

Figure 1.

Figure 1

Multimodal image of case 1. CFP: Color fundus photography, FAF: Fundus autofluorescence, FA: Fluorescein angiography, OCT-A: Optical coherence tomography angiography

The patient was treated with methotrexate (15 mg/week), oral prednisone (1 mg/kg/day), and prednisolone acetate eye drops. Two months later, visual acuity was 20/20 in OD and 20/200 in OS. The fundus lesions appeared more pigmented, and choroidal atrophy appeared at the retinal equator, but there were no new choroiditis spots. The retinal vessels were thinner compared with the first fundus photograph. The FA patterns remained the same as the previous one.

Fifteen days later, visual acuity decreased again to 20/60 in OD and 20/400 in OS without significant changes in biomicroscopy, cellularity, and IOP in OU. The clinical presentation, combined with multimodal imaging findings, confirmed the diagnosis of RPC. The patient subsequently received intravenous cyclophosphamide (10 mg/kg/dose) as rescue therapy, which achieved disease control. Given the recurrent nature of RPC and the favorable initial response to cyclophosphamide, maintenance immunosuppression with oral methotrexate was reinstated. At one-year follow-up, the patient maintained excellent visual outcomes (20/20 OD, 20/50 OS) with complete quiescence of inflammatory activity. Fundus examination demonstrated extensive lesion pigmentation without evidence of new choroiditis spots, indicating disease stability [Fig. 2].

Figure 2.

Figure 2

Color fundus photography evolution of patient 1 during follow-up

Second Case

A 19-year-old woman presented with bilateral visual loss for two months. She stated no systemic symptoms and denied having any diseases. She was initially diagnosed with ocular toxoplasmosis by an outside facility and treated with oral steroids. The BCVA was 20/63 in OD and 20/50 in OS. Intraocular pressure was 15 and 14 mmHg, respectively. No cells or flare were seen in the anterior chamber, and only a few cells were observed in the vitreous chamber. The fundus was asymmetric in OU and had multiple atrophic retinal lesions that were widespread at the posterior pole [See Fig. 3].

Figure 3.

Figure 3

Color fundus photography of cases 2, 3, and 4

VDRL, FTA–Abs, and PPD tests were performed to rule out infection. She was treated with two intravenous cyclophosphamide pulses (800 mg each, administered one month apart) combined with oral prednisone (1 mg/kg/day). The patient demonstrated significant clinical improvement at one-month follow-up. BCVA improved to 20/30 OD and 20/50 OS, with complete resolution of vitreous cells and no anterior chamber inflammation. Given this favorable response, maintenance immunosuppression with oral methotrexate was initiated to prevent disease recurrence. This therapeutic strategy proved effective, with maintained visual acuity at the 4-month follow-up examination.

Third Case

A 15-year-old male patient showed progressive deterioration of visual acuity in OU over the past six weeks. Flu-like symptoms preceded the ocular involvement, with no other known systemic signs. He was treated externally with oral corticosteroids without success. BCVA was 20/80 in OU, and IOP was 18 and 19 mmHg, respectively; no cellularity or flare was found in the anterior chamber in OU. Vitreous cells and white placoid lesions were observed at the posterior pole of OU, some of which were active, and others were in a scarred state. VDRL, FTA–Abs, and PPD tests were performed to rule out infection.

Based on the characteristic clinical presentation and multimodal imaging findings, a diagnosis of RPC was established. The patient underwent pulsed intravenous cyclophosphamide therapy (800 mg monthly for two consecutive months) after demonstrating suboptimal response to prior corticosteroid treatment. Following initial therapy, BCVA improved to 20/50 OU, prompting administration of an additional cyclophosphamide pulse (800 mg IV) to consolidate the therapeutic response. In light of the disease’s recurrent nature and the patient’s favorable response to immunosuppression, maintenance therapy with oral methotrexate (15 mg weekly with folate supplementation) was initiated as a steroid-sparing strategy. This therapeutic approach resulted in sustained clinical improvement, with visual acuity reaching 20/20 OD and 20/40 OS at the six-month follow-up evaluation.

Fourth Case

A 31-year-old male patient presented with a one-month loss of vision in his OD. He denied known diseases and systemic symptoms; he has been using tobacco and methamphetamine for 2 years. His BCVA was 20/400 in OD and 20/20 in OS; no changes were noted in the anterior segment of OU. The vitreous was transparent without cellularity; the posterior pole showed chorioretinal lesions and scars in OU. The macular OCT showed general retinal thickening and irregularities at the level of the retinal pigment epithelium (RPE) in the affected areas of OU. Blood chemistry, urine test, and hematologic biometry were normal. VDRL, FTA–Abs, PPD, RF, and ANA were all negative.

He was treated with a daily bolus of methylprednisolone (1 g) for 3 days and a bolus of intravenous cyclophosphamide (1 g). One month later, vision improved to 20/100 in OD and 20/20 in OS; IOP was 14 mmHg and 13 mmHg, respectively. Given the persistent asymmetry in visual recovery and the known relapsing nature of RPC, the patient subsequently received three additional monthly cyclophosphamide pulses (1 g IV monthly) as consolidation therapy. This regimen achieved further visual improvement in the affected right eye (20/63 at 5-month follow-up) while maintaining stability in the left eye (20/20). Considering the favorable therapeutic response but recognizing the risk of disease recurrence, maintenance immunosuppression with oral methotrexate was initiated. Throughout the treatment course, no ocular hypertension or other treatment-related adverse effects were observed.

Discussion

RPC was first described by Jones et al.[1] Their initial report included six patients, aged between 17 and 51 years, without sex predilection, who presented with a white dot syndrome featuring characteristics of APMPPE and serpiginous choroiditis. At that time, they noted the atypical time course and extensive retinal distribution of the findings.

In our case series, there was no sex predilection, with patients aged between 15 and 31 years, and all patients had sudden and painless asymmetric vision loss, which is consistent with other previous reports.[2,4] The mean follow-up period for our patients was 6.75 months. Only one patient had a viral prodrome, while the others had no systemic signs or relevant medical history. None of the patients displayed anterior chamber inflammation, and half had mild asymmetric vitreous haze that did not hinder posterior pole assessment. Retinal lesions were asymmetric and widely distributed in the posterior pole. Laboratory tests, including VDRL, FTA–Abs, and PPD, were normal in all patients, except for one case of leukocytosis [see Table 1]. The primary treatment consisted of steroids and IV pulses of cyclophosphamide as an emergency intervention. Following induction treatment, all patients were transitioned to oral methotrexate 2–4 weeks after the final cyclophosphamide bolus as maintenance immunosuppression to prevent disease recurrence.”

Table 1.

Laboratory results in all patients resumed

Normal results Abnormal results
Blood count – Serum electrolytes – Blood chemistry – Liver function test C protein
VDRL – FTA–ABs – PPD – AntiTB Ab LT 902 (CD8/CD4)
IgG and IgA levels IgM and IgE levels
Anti-EBV IgM Anti-EBV IgG
RF – ANA – C3 –C4
C ANCA – P ANCA – Anti-DNA
Intradermic histoplasmosis and coccidiomicosis tests

In our four patients, the mean initial BCVA was 20/125 (0.8 LogMar). BCVA was asymmetric between the two eyes, with a mean BCVA of 20/40 (0.3 LogMar) in the better eye and 20/320 (1.2 LogMar) in the worse eye. The mean final BCVA improved to 20/32 (0.2 LogMar), with the better eye averaging 20/25 (0.1 LogMar) and the worse eye 20/50 (0.4 LogMar). Therefore, treatment with IV cyclophosphamide resulted in a statistically significant improvement in final BCVA (P < 0.001) in patients with RPC [see Table 2].

Table 2.

Clinical characteristics, therapeutic interventions, and visual outcomes in the four cases of relentless placoid choroiditis

Patients Case 1 Case 2 Case 3 Case 4
Age 20 years 19 years 15 years 31 years
Initial BCVA 0.3 (20/40) 2.5 (CD 1F) 0.5 (20/63) 0.4 (20/50) 0.6 (20/80) 0.6 (20/80) 1.3 (20/400) 0.0 (20/20)
Treatment Cyclophosphamide IV
Methotrexate PO
Prednisone PO Prednisolone drops
Cyclophosphamide IV
Prednisone PO
Methotrexate PO
Cyclophosphamide IV
Methotrexate PO
Cyclophosphamide IV
Methylprednisolone IV
Methotrexate PO
Months of follow-up 12 months 4 months 6 months 5 months
Final BCVA 0.0 (20/20) 0.4 (20/50) 0.2 20/30 0.4 (20/50) 0.0 (20/20) 0.3 (20/40) 0.5 (20/63) 0.0 (20/20)

BCVA=best-corrected visual acuity (LogMAR values with Snellen equivalents in parentheses); CD1F=counting fingers at 1 foot; IV=intravenous; PO=per OS (oral administration). Treatment doses and follow-up durations are specified for each case

OCT findings in RPC are rarely reported. In one case, a foveal lesion, subretinal fluid, and pigment epithelial detachment were observed. Reflectivity changes were present in both inner and outer retinal layers, corresponding to clinical lesions and autofluorescence photography. Our findings align with these observations, highlighting distinct areas of inflammation in the outer retinal layers and RPE.[7]

There is a lack of consensus on the treatment of RPC, and the use of cyclophosphamide in this condition has not been extensively studied. Recent reports have suggested that adalimumab may be effective in RPC, helping reduce the required dosage of systemic immunosuppressants.[9] However, several factors influenced our therapeutic selection cost constraints and limited availability of biologic agents in our clinical setting; the well-documented steroid-sparing efficacy and favorable safety profile of methotrexate for maintenance therapy; rapid, sustained clinical response to cyclophosphamide-methotrexate sequencing in our cohort; and insufficient comparative evidence demonstrating superior efficacy of mycophenolate mofetil or anti-TNF agents over conventional immunosuppressants for RPC.

Cyclophosphamide is a cell cycle non-specific alkylating agent. IV pulse cyclophosphamide has proven effective in severe or refractory ocular inflammatory diseases.[10] After an intravenous dose, peak concentrations of active metabolites are reached approximately two hours post-administration. Little difference has been noted between IV and oral cyclophosphamide. Due to its rapid immunosuppressive effect, it is used in bolus form during acute episodes of systemic autoimmune diseases.[11,12,13,14]

In our case series, pulse therapy was able to control inflammation immediately after initiation of treatment, and side effects were minimal, with only one patient reporting nausea and hair loss. All patients were examined for infectious diseases, and blood and urine tests were also performed. Before treatment, patients received premedication with antiemetic drugs. Treatment with cyclophosphamide was well tolerated, with only minor side effects, and no patient required discontinuation of treatment.

These findings contribute to the growing body of evidence supporting the efficacy of cyclophosphamide in serpiginous-spectrum of posterior uveitis. A randomized controlled trial demonstrated that pulse cyclophosphamide achieved superior lesion resolution kinetics (median: 2 weeks) in macular serpiginous choroiditis compared to pulse corticosteroid therapy, despite comparable long-term relapse rates between treatment arms.[15] Subsequent research using an intensive cyclophosphamide regimen (1 g/m² ×3 days) provided rapid disease control in macular-threatening serpiginous choroiditis, with sustained visual acuity improvement from 0.71 ± 0.35 logMAR at baseline to 0.31 ± 0.23 at 12-month follow-up (P ≤ 0.05[16] Our study extends these observations by demonstrating application to RPC’s more aggressive phenotype. In our case series, combining cyclophosphamide pulses proved highly effective for RPC’s recalcitrant course, demonstrating rapid inflammatory control (all cases responding immediately after treatment initiation) and an excellent safety profile (only one patient reporting transient nausea and hair loss, with no treatment discontinuations).

In the present report, only four cases were studied, and a standard therapy for RPC has yet to be established. Therefore, further studies with larger patient cohorts are necessary to confirm the efficacy of intravenous cyclophosphamide in treating RPC. Despite the promising results, our study is limited by the small sample size and short follow-up period. Additional research with a larger number of patients and longer follow-up periods is essential to validate the effectiveness of intravenous cyclophosphamide in RPC and to develop standardized treatment protocols.

Conclusion

In this case series, cyclophosphamide significantly improved visual acuity, suppressed disease activity, and stabilized retinal lesions with minimal side effects, suggesting it as a safe, effective, and cost-efficient treatment option. These findings are particularly relevant for resource-limited settings where access to biologics may be constrained. However, the small sample size and short follow-up period limit the generalizability of our results. Further studies with larger cohorts and longer follow-up are needed to validate these findings and establish standardized treatment protocols. Cyclophosphamide represents a promising therapeutic alternative for RPC, especially in refractory cases, and warrants further investigation in the management of this rare and vision-threatening condition.

Conflicts of interest:

There are no conflicts of interest.

Funding Statement

Nil.

References

  • 1.Jones BE, Jampol LM, Yannuzzi LA, Tittl M, Johnson MW, Han DP, et al. Relentless placoid chorioretinitis: A new entity or an unusual variant of serpiginous chorioretinitis? Arch Ophthalmol. 2000;118:931–8. [PubMed] [Google Scholar]
  • 2.Jyotirmay B, Jafferji SS, Sudharshan S, Kalpana B. Clinical profile, treatment, and visual outcome of ampiginous choroiditis. Ocul Immunol Inflamm. 2010;18:46–51. doi: 10.3109/09273940903402637. [DOI] [PubMed] [Google Scholar]
  • 3.Yeh S, Forooghian F, Wong WT, Faia LJ, Cukras C, Lew JC, et al. Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol. 2010;128:46–56. doi: 10.1001/archophthalmol.2009.368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Raven ML, Ringeisen AL, Yonekawa Y, Stem MS, Faia LJ, Gottlieb JL. Multi-modal imaging and anatomic classification of the white dot syndromes. Int J Retina Vitreous. 2017;3:12. doi: 10.1186/s40942-017-0069-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Steptoe PJ, Pearce I, Beare NAV, Sreekantam S, Mohammed BR, Barry RJ, et al. Proposing a neurotropic etiology for acute posterior multifocal placoid pigment epitheliopathy and Relentless placoid chorioretinitis. Front Ophthalmol. 2022;1:7. doi: 10.3389/fopht.2021.802962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lambrecht P, Claeys M, De Schryver I. A case of ampiginous choroiditis. Case Rep Ophthalmol. 2015;6:453–7. doi: 10.1159/000442742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Amer R, Florescu T. Optical coherence tomography in relentless placoid chorioretinitis. Clin Exp Ophthalmol. 2008;36:388–90. doi: 10.1111/j.1442-9071.2008.01773.x. [DOI] [PubMed] [Google Scholar]
  • 8.Uraki T, Namba K, Mizuuchi K, Iwata D, Ohno S, Kitaichi N, et al. Cyclosporine and prednisolone combination therapy as a potential therapeutic strategy for relentless placoid chorioretinitis. Am J Ophthalmol Case Rep. 2019;14:87–91. doi: 10.1016/j.ajoc.2019.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Asano S, Tanaka R, Kawashima H, Kaburaki T. Relentless placoid chorioretinitis: A case series of successful tapering of systemic immunosuppressants achieved with adalimumab. Case Rep Ophthalmol. 2019;10:145–52. doi: 10.1159/000500077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: Efficacy and short-term safety. Ophthalmology. 2004;111:960–5. doi: 10.1016/j.ophtha.2003.08.034. [DOI] [PubMed] [Google Scholar]
  • 11.Scott DGI, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76:377–84. doi: 10.1016/0002-9343(84)90654-5. [DOI] [PubMed] [Google Scholar]
  • 12.Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis. 2004;63:525–9. doi: 10.1136/ard.2002.003574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85:351–8. [PubMed] [Google Scholar]
  • 14.Martin-Suarez I, D’Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GRV. Immunosuppressive treatment in severe connective tissue diseases: Effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997;56:481–7. doi: 10.1136/ard.56.8.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Venkatesh P, Tayade A, Gogia V, Gupta S, Shah BM, Vohra R. Short-term intensive immunosuppression: A randomized, three-arm study of intravenous pulse methylprednisolone and cyclophosphamide in macular serpiginous choroiditis. Ocul Immunol Inflamm. 2018;26:469–76. doi: 10.1080/09273948.2016.1237663. [DOI] [PubMed] [Google Scholar]
  • 16.Venkatesh P, Gogia V, Gupta S, Tayade A, Shilpy N, Shah BM, et al. Pulse cyclophosphamide therapy in the management of patients with macular serpiginous choroidopathy. Indian J Ophthalmol. 2015;63:318–22. doi: 10.4103/0301-4738.158070. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Indian Journal of Ophthalmology are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES